Meet the Team

Our team combines extensive industry experience with deep functional domain knowledge

Gamma was founded in 2019 in partnership with investment firm KKR & Co. to address the need for next generation biomanufacturing tools and technologies to support the rapid innovation in advanced biological therapies.

Since our formation, we have deployed nearly $300M into early and mid-stage businesses making an impact on across the highest value segment of the biomanufacturing value chain.

CEO Matt Gunnison

MATT GUNNISON
Founder & CEO

Matt oversees the Gamma portfolio and is responsible for identifying and executing investments as well as driving growth, strategic and operational initiatives and business development activities at Gamma’s portfolio companies. Matt was most recently Global Head of Business Development for GE Healthcare, where he was responsible for M&A and strategic alliances across the $19B division of GE. Matt joined GE in 2011 and held a variety of other leadership positions in strategy, business development, venture investing and new business creation during his nearly nine years at the company. Matt began his career as a corporate attorney at Sidley Austin LLP. He holds a J.D. from the University of Michigan and a B.A. in Economics from Georgetown University.

MATT GUNNISON
PARTNER & CTO PHIL VANEK

PHIL VANEK
PARTNER & CTO

Phil is responsible for technical due diligence and evaluation of potential investments, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies. An entrepreneurial and strategic international business leader, Phil joins Gamma from GE Healthcare’s Cell and Gene Therapy business unit where he directed strategy and portfolio growth. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center followed by an IRTA fellowship at the National Cancer Institute in Maryland, and at the Hollings Cancer Center in Charleston, SC. Phil was an instructor for Johns Hopkins University Advanced Academic Programs teaching Biotechnology Marketing in the Masters of Biotechnology / MBA program, and has held leadership positions in a number of life sciences companies including Life Technologies, Becton Dickinson, and Lonza. Phil is a Board Member of CCRM in Toronto Canada and a Board Member of the ARM Foundation.

PHIL VANEK

ERIC SIMPSON
PRINCIPAL

Eric focuses on financial diligence and deal execution for new investments, and ongoing portfolio management. Prior to joining Gamma Eric led product management for Zymergen, a biomanufacturing company, where he oversaw technology development for new capabilities including bioinformatics and data science. Eric began his career as a consultant with Bain & Company, advising on technology strategy and M&A due diligence. He holds a B.S. in Materials Science Engineering and Economics from Northwestern University and an MBA from Harvard Business School.

ERIC SIMPSON

KIERAN MURPHY
CHAIRMAN

Kieran was most recently President and Chief Executive Officer of the $19B Healthcare division of General Electric. Prior to overseeing GE Healthcare, he was president and CEO of GE Healthcare Life Sciences, a global leader in life sciences tools and diagnostics providing a broad range of technologies and services for biopharmaceutical research, development and manufacturing. Under Kieran’s’s leadership, GE Healthcare Life Sciences emerged as a market leader in the bioprocessing industry. Prior to joining GE, Kieran served as CEO of Whatman plc, a global supplier of filters and membranes for life sciences applications

KIERAN MURPHY